5th Scientific Summit in Athens: success for the Replica project

CoEHAR Director Giovanni Li Volti and the co-project leader of the Replica project Massimo Caruso have been invited to be part of the 5th Scientific Summit on Harm Reduction in Athens to deliver a presentation on the latest results obtained by the Replica project and their implication for public health.

Continue Reading5th Scientific Summit in Athens: success for the Replica project

Replica project results at the XVI FISV Congress in Naples

The Replica project team activity and the results of the studies on the reduced cytotoxicity and inflammation induced by cigarette smoke and ENDS aerosol will be presented during the XVI edition of the Congress of the Italian Federation of Life Sciences (FISV), which represents over 10.0000 Italian scientists and which will take place from 14 to 16 September 2022 in Naples

Continue ReadingReplica project results at the XVI FISV Congress in Naples

75th Tobacco Science Research Conference: CoEHAR in New Orleans 

The meeting “75th Tobacco Science Research Conference” is an incredible opportunity for researchers and professionals to discuss, analyze and deepen the latest news on tobacco harm reduction strategies, including the necessary steps to develop the scientific activity and the engagement of the sector

Continue Reading75th Tobacco Science Research Conference: CoEHAR in New Orleans 

US: end of teen nicotine vaping epidemic and eradication of tobacco smoking

The use of e-cigarette among teenagers in the United States is considered a significant public health problem. A close look at federal data now show that the number of young e-cigarette users has markedly declined to below epidemic levels since its peak in 2019.

Continue ReadingUS: end of teen nicotine vaping epidemic and eradication of tobacco smoking

First study in the world to evaluate efficacy and safety of the antismoking drug varenicline for smokers with Diabetes

A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus

Continue ReadingFirst study in the world to evaluate efficacy and safety of the antismoking drug varenicline for smokers with Diabetes

The first review to assess the metabolic impact of stopping smoking in patients with diabetes mellitus revealed serious gaps in the literature

Quitting smoking can reduce cardiovascular and kidney failure risks. However, it can lead to side effects such as weight gain. A scoping review conducted by a pool of European researchers revealed a lack of data on the metabolic effects of smoking and smoking cessation in diabetes. Healthcare professionals should not assume that cessation of smoking will improve metabolic parameters in patients with diabetes.

Continue ReadingThe first review to assess the metabolic impact of stopping smoking in patients with diabetes mellitus revealed serious gaps in the literature

No Tobacco Day, 31 May 2022: smoker number increased, concrete answers needed 

Yesterday, the Italian Ministry of Health released new data on smoking prevalence: there are 800000 more smokers in the country than in 2019. Rates increased especially among women and young people. The report found that also the numbers of the users of heated tobacco products and electronic cigarettes is rising. “An expected disaster, partly anticipated by our data published in 2020 and obtained thanks to a study conducted during the acute phase of Covid-19 pandemic. Since then, no prevention policies, no answers from the Italian health authorities. Reporting a disaster is not enough: we need to come up with alternative and effective solutions”. Stated professor Riccardo Polosa, founder of the CoEHAR, who opened the first National Conference on Tobacco Harm Reduction.

Continue ReadingNo Tobacco Day, 31 May 2022: smoker number increased, concrete answers needed